Please login to the form below

Not currently logged in
Email:
Password:

Ironwood promotes Dr Mark Currie

He moves up to chief scientific officer at the US pharma company

Ironwood Pharmaceuticals Dr Mark CurrieIronwood Pharmaceuticals has promoted Dr Mark Currie to senior vice president, chief scientific officer and president of R&D.

He previously led the Cambridge, Massachusetts-based company's R&D efforts, having joined the firm in 2002.

Prior to this he directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor and before that served as director of arthritis and inflammation at Monsanto Company.

Ironwood's CEO Peter Hecht said: “Mark's outstanding contributions to Ironwood, including his expertise, leadership and superb judgment, are invaluable as we move our R&D efforts forward, growing our active pipeline and expanding our development efforts globally on behalf of our shareholders and the patients we aim to serve.”

Currie's academic research on the guanylate cyclase-C (GC-C) pathway laid the foundation for the discovery by Ironwood scientists of linaclotide.

Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.

19th February 2013

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...